TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05641259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-108
Description: Oral administration for 21 or 28 days on a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-108
Description: Oral administration for 21 or 28 days on a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-108
Description: Oral administration for 21 or 28 days on a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-108
Description: Oral administration for 21 or 28 days on a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous administration for 7 days on a 28-day cycle at the dose of 75mg/m2 2-2.5h hours after LP-108.
Study: NCT05919173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 0.25% Injection Solution
Description: Bupivacaine Hydrochloride 0.25% Injection Dose: 1mL/kg (milliliter per kilogram body weight)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 0.25% Injection plus Dexmedetomidine 1 microgram/kg body weight
Description: Bupivacaine HCL 0.25% Injection plus Dexmedetomidine 1micro/kg Dose: 1 mL/kg (milliliter per kilogram body weight)
Study: NCT05821062

Intervention type: OTHER
Intervention: standard Aspirin (ASA) + clopidogrel (CLP) therapy
Description: ASA100mg + CLP 75mg daily

Intervention type: OTHER
Intervention: standard Aspirin (ASA) + clopidogrel (CLP) therapy
Description: ASA100mg + CLP 75mg daily

Intervention type: OTHER
Intervention: standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy
Description: ASA 100 mg + TCG 90mg/b.i.d or PSG10mg daily

Intervention type: OTHER
Intervention: standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy
Description: ASA 100 mg + TCG 90mg/b.i.d or PSG10mg daily

Intervention type: OTHER
Intervention: standard ASA therapy
Description: ASA 100 mg daily

Intervention type: OTHER
Intervention: standard ASA therapy
Description: ASA 100 mg daily
Study: NCT05234697

Intervention type: DRUG
Intervention: Remifentanil
Description: Remifentanil was used for maintenance of anesthesia.

Intervention type: DRUG
Intervention: Remifentanil
Description: Remifentanil was used for maintenance of anesthesia.
Study: NCT05651061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SS109
Description: 27 patients are enrolled in cohorts ,and will continue to be followed up until 28 days after SS109 administration for evaluating safety, PK/PD and immunogenicity.
Study: NCT06204640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Spironolactone will be start at 25 mg per day initially then titrated to a maximum of 50 mg per day in the absence of contraindication at the 1-month study visit.
Study: NCT05945342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: The US Food and Drug Administration(FDA) has only approved fluoxetine and escitalopram for the treatment of adolescent depression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal Psychotherapy for Adolescent
Description: Interpersonal Psychotherapy for Adolescent(IPT-A), A modified version of interpersonal psychotherapy, is shorter than the standard therapy duration (12-16 sessions), with a total of eight sessions, retaining the structure of the standard IPT but employing a series of strategies to extract the most important components to speed up the time process.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escitalopram combined with psychotherapy
Description: The subjects received adolescent interpersonal psychotherapy for adolescent(IPT-A) while taking medication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escitalopram combined with rTMS
Description: The subjects received Robotic navigational repetitive transcranial magnetic stimulation while taking medication

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Escitalopram combined with sham rTMS
Description: The subjects received sham Robotic navigational repetitive transcranial magnetic stimulation while taking medication
Study: NCT05853991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: osteopathic manipulative treatment
Description: The intervention will be based on the specific assessment and treatment of the preterm developed by the team and validated through different studies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Application of affective touch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of static touch
Study: NCT05336591

Intervention type: OTHER
Intervention: Covid-19 pandemic
Description: All participants worked during the Covid-19 pandemic in the preventive or curative healthcare for children with overweight and obesity. We will ask all professionals about their experiences during and after the pandemic.

Intervention type: OTHER
Intervention: Covid-19 pandemic
Description: All participants worked during the Covid-19 pandemic in the preventive or curative healthcare for children with overweight and obesity. We will ask all professionals about their experiences during and after the pandemic.

Intervention type: OTHER
Intervention: Covid-19 pandemic
Description: All participants worked during the Covid-19 pandemic in the preventive or curative healthcare for children with overweight and obesity. We will ask all professionals about their experiences during and after the pandemic.

Intervention type: OTHER
Intervention: Covid-19 pandemic
Description: All participants worked during the Covid-19 pandemic in the preventive or curative healthcare for children with overweight and obesity. We will ask all professionals about their experiences during and after the pandemic.
Study: NCT05938400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyvinylsiloxane impression with different techniques
Description: One step impression technique will be compared with the standard two step technique

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyvinylsiloxane impression with different techniques
Description: One step impression technique will be compared with the standard two step technique
Study: NCT06001073

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.

Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.
Study: NCT05251324

Intervention type: OTHER
Intervention: Hot Flush Induction
Description: A temperature-controlled, water-circulating heating pad at a constant temperature of 107˚F will be placed on the participant's torso, a microwaved heating neck pad will be placed on the participant's neck, and two warm balloons will be placed in the participant's hands for 30 min. Subjective (verbal start and end point to be marked on LabChart software) and objective (skin conductance and skin temperature) measures of hot flushes will be recorded.

Intervention type: OTHER
Intervention: Hot Flush Induction
Description: A temperature-controlled, water-circulating heating pad at a constant temperature of 107˚F will be placed on the participant's torso, a microwaved heating neck pad will be placed on the participant's neck, and two warm balloons will be placed in the participant's hands for 30 min. Subjective (verbal start and end point to be marked on LabChart software) and objective (skin conductance and skin temperature) measures of hot flushes will be recorded.
Study: NCT04799912

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Elective labor induction
Description: Elective labor induction at 39 weeks of gestation
Study: NCT06317740

Intervention type: OTHER
Group type: OTHER
Intervention: green management intervention program
Description: The program activities focused on integrating green management concepts into both theory and practice learning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: green management intervention program
Description: The program activities focused on integrating green management concepts into both theory and practice learning
Study: NCT06071806

Intervention type: OTHER
Group type: OTHER
Intervention: Topical Application of 5-Fluorouracil
Description: The entire cyst lining radically enucleated in conjunction with any overlying mucosa, followed by extensive cavity thorough curettage, peripheral ostectomy was carried out for all bony walls to remove the microscopic satellite cyst, with identification, isolation, retraction, and preservation of the lingual and inferior alveolar bundle,a sterile radiopaque quarter-inch ribbon gauze coated with 5-FU cream was packed into the surgical wound. Closure of the wound was then done in the usual manner using 3/0 vicryl leaving approximately1 cm of a small distal end of the gauze exposed to allow for easy removal after 24 hours postoperatively
Study: NCT04924881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVID Rehab Formula granules
Description: COVID Rehab Formula granules once daily for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo granules
Description: Placebo granules once daily for 8 weeks
Study: NCT05482100

Intervention type: DIAGNOSTIC_TEST
Intervention: Patients monitored with OmniGraf testing
Description: This is an observational study there are no protocol mandated interventions. OmniGraf results will be utilized in conjunction with standard of care assessments to determine patient management.
Study: NCT04406857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropidoxuridine
Description: Given PO
Study: NCT05201313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: nebulization of 3 puffs of 10 mL Lidocaine hydrochloride 10% spray at a distance of 4-5 cm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine Injection
Description: subcutaneous / submucosal infiltration depending on the type of perineal tear of 10 ml of 1% mepivacaine hydrochloride
Study: NCT05237076

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperinsulemic-Euglycemic Clamp & Hypoxic Ventilatory Response (HVR)
Description: Hyperinsulemic-Euglycemic Clamp as described by deFronzo et al.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinsulemic-Euglycemic Clamp & Hypoxic Ventilatory Response (HVR)
Description: Hyperinsulemic-Euglycemic Clamp as described by deFronzo et al.
Study: NCT06226493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous vagus nerve stimulation
Description: The Parasym Plus device (https://parasym.io) is a transcutaneous auricular vagus nerve stimulator that has been deemed non-significant risk (NSR) by the FDA. Transcutaneous auricular vagus nerve stimulator is a non-significant risk device, as it involves electrical stimulation of the external ear using an ear clip, with no invasive components. The stimulation parameters will be limited to the confines of existing published data. tVNS is safe and well tolerated at doses tested in research studies. The Parasym device is considered low risk when used in accordance with the instructions for use. Participants will be properly trained to use the device, and those with contraindications will be excluded for extra precaution. A low incidence of skin irritation has been reported. No serious adverse events have been reported.
Study: NCT05635253

Intervention type: OTHER
Group type: OTHER
Intervention: Hydrogen Peroxide 35%
Description: Group that received only bleaching treatment. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide 35% + Polishing whitened teeth
Description: Group that received only bleaching treatment followed by polishing. Soft tissue protection was performed with a Top Dam light-curing gingival barrier (FGM, Santa Catarina, SC, Brazil). Application of whitening gel (Whitness HP 35%/FGM) on the buccal surface from premolar to premolar in the upper and lower arches. Three 45-minute sessions were held with an interval of seven days between them. After bleaching, the vestibular surfaces were polished for 20s on each bleached tooth, with polishing paste and felt disc (Diamond Flex, FGM, Santa Catarina, SC, Brazil) in low rotation.
Study: NCT05377255

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 16 mg naloxone AP003
Description: 4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 16 mg naloxone AP003
Description: 4 doses of 4 mg each (total: 16 mg) of naloxone through the AP003 device

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 8 mg naloxone NARCAN Nasal Spray
Description: 2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: 8 mg naloxone NARCAN Nasal Spray
Description: 2 doses of 4 mg each (total: 8 mg) of the naloxone through the NARCAN Nasal Spray device
Study: NCT06517589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Process-based Cognitive Behavioral Therapy (PBT)
Description: PBT (20 sessions), intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT (20 sessions), intervention planning as usual based on manual.
Study: NCT05017272

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Addiction Recovery Support Software Platform
Description: OARS (Opioid Addiction Recovery Support) is used by providers of MAT programs to improve insight into a patient's recovery progress while promoting ownership and adherence to treatment plans. OARS also provides extensive tools to support patients with recovery from Opioid Use Disorder.
Study: NCT06209307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor physical therapy
Description: Pelvic floor physical therapy (i.e., Kegel exercises):~* Finding the right muscles: To identify pelvic floor muscles, the patient should stop urination in midstream or tighten the muscles that keep from passing gas. These maneuvers use pelvic floor muscles. Once the pelvic floor muscles are identified, the patient can do the exercises in any position, although doing them lying down at first might be the easiest approach.~* Perfecting the technique: Tighten pelvic floor muscles, hold the contraction for three seconds, and then relax for three seconds. Try it a few times in a row. When muscles get stronger, try doing Kegel exercises while sitting, standing, or walking.~* Maintaining focus: For best results, focus on tightening only pelvic floor muscles. Be careful not to flex the muscles in the abdomen, thighs, or buttocks. Avoid breath-holding. Instead, breathe freely during the exercises.~* Repeat 3 times a day. Aim for three sets of 10 repetitions a day.
Study: NCT06003270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin 1000 mg
Description: Active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quercetin 500 MG
Description: Active comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT05724095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high frequency acupoint stimulation
Description: electrodes are attached to area of acupoints and electrical stimulation at 10/50 Hz is given

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low frequency acupoint stimulation
Description: electrodes are attached to area of acupoints and electrical stimulation at 2/10 Hz is given

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: electrodes attached
Description: electrodes are attached to area of acupoints

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrodes attached
Description: electrodes are attached to area of acupoints

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrodes attached
Description: electrodes are attached to area of acupoints
Study: NCT05166200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Formula
Description: Diabetes-specific study formula

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test Meal
Description: Instant oatmeal
Study: NCT06061549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a
Description: 3E13 viral genomes fixed dose
Study: NCT05536765

Intervention type: PROCEDURE
Intervention: Surgical exposure of impacted tooth
Description: The therapeutic approach of surgical exposure of impacted teeth is performed by preparing a flap and removing the cortical bone around the crown of the teeth.~This procedure provides optimal conditions for the orthodontist. In fact, surgical exposure allows the orthodontist to bond the impacted tooth in the correct position depending on the intended direction to apply the correct traction forces for alignment.
Study: NCT04543279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib will be supplied by Rigel Pharmaceuticals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib will be supplied by Rigel Pharmaceuticals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is commercially available.
Study: NCT05656144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: AK104, 6mg/kg, Q2W
Study: NCT05805917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neoviderm Skin Emulsion medical device
Description: Neoviderm Skin Emulsion will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Connettivina 0.2% Cream
Description: Connettivina 0.2% Cream will be applied twice daily, to cover the entire cutaneous surface interested by burns, followed by a gentle massage to spread the product evenly of all the affected skin.
Study: NCT06131736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tabata Training
Description: This training program, lasting about 20 minutes, was repeated three times a week for a total of 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cluster Training
Description: The movements were performed in 3 sets, each set containing 9 repetitions with 60-90 seconds of rest between each two sets.
Study: NCT06520774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Concave Supra-arch Branched Stent-Graft System
Description: To evaluate the efficacy and safety of Concave Supra-arch Branched Stent-Graft System for endovascular treatment of Aortic Arch Diseases
Study: NCT06437041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ornidazole
Description: Patients will receive three consecutive enemas of ornidazole 0.5g+50ml saline through the TET tube, followed by WMT treatment once daily for a duration of 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive three consecutive enemas of placebo of equal volume through the TET tube, followed by WMT treatment once daily for a duration of 3 days
Study: NCT05717543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retro-illuminator
Description: The device Retro-illuminator will be used to photograph the eyes.
Study: NCT06431997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-limited eating
Description: All participants will be instructed to follow a diet of 1800-2200 kcal/d (45-50% of energy from carbohydrate, 15-20% from protein, 25-30% from fat) based primarily on Dietary Guidelines for Chinese Residents (2022), Dietary guidelines for pregnant women and Guideline of Diagnosis and Treatment of Hyperglycemia in Pregnancy (2022). Participants assigned to the TRE group will be instructed to consume prescribed calories in a 10-hour eating window (from 8:30 am to 18:30 pm) each day and only noncaloric beverages were permitted outside of the eating window over 3 months (from 14-26 gestational weeks). Participants in the SOC group will be instructed to consume prescribed calories following habitual daily eating schedule over 3 months.
Study: NCT05653869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APS03118
Description: Participant received APS03118 orally until evidence of unacceptable toxicity, progressed disease, consent withdrawal or with drawl from the study at the discretion of the investigator.
Study: NCT05915910

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: blood donation

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: blood donation

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: blood donation

Intervention type: DIAGNOSTIC_TEST
Intervention: Specimen Donation
Description: blood donation